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Abstract
Background: Insulin is the recommend therapeutic agent of choice for the management of Cystic
Fibrosis Related Diabetes (CFRD), despite only sub-optimal reductions in glycemic control and
increased morbidity and mortality reported by centers using this agent. The newer insulin
sensitizing agents demonstrated to have anti-inflammatory mechanisms may provide an alternative
management option for CFRD.
Methods:  A prospective case based therapeutic comparison between insulin, sulfonylurea,
metformin and thiazolidinedione was observed over one decade with 20 CFRD patients diagnosed
using American Diabetes Association guideline standards. Patients entering the study elected
treatment based on risk and benefit information provided for treatment options. Patients receiving
organ transplant or requiring combination diabetic medications were excluded from the study.
Results: No statistical advantage was achieved regarding overall glycemic control for oral agents
over insulin. Additional outcome measures including changes in weight, liver function testing and
FEV1 were not statistically significant.
Conclusion: Insulin alone may not be the only therapeutic option in managing CFRD. Oral
hypoglycemic agents were equally effective in treating CFRD and may provide an alternative class
of agents for patients reluctant in using insulin.
Background
Diabetes mellitus has a 15–30% prevalence in cystic fibro-
sis (CF) patients [1]. Only 33% of diabetic CF patients are
symptomatic for diabetes [2]. This subtle presentation of
diabetes has resulted in the Cystic Fibrosis Foundation
recommending screening guidelines for diabetes [3]. This
guideline further recommends insulin as the therapeutic
agent of choice in managing Cystic Fibrosis Related Dia-
betes (CFRD). Current recommendations for insulin are
not always feasible for CFRD patients due to poor compli-
ance and hypoglycemia. Diabetic diets utilized for type 1
and 2 diabetes conflict with the high fat and carbohydrate
diet required to compensate for the malabsorption associ-
ated with the majority of CF patients. This carbohydrate
load further stresses glucose tolerance in CF that is associ-
ated with both impaired insulin secretion and insulin
resistance [4]. Increasing insulin resistance is correlated
with progressive development of impaired glucose toler-
ance in CF [5,6]. Insulin deficiency progresses with
increasing age, but is seldom absolute in CF and ketoaci-
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dosis is uncommon [7]. This disease process may there-
fore respond to medications used in the management of
type 2 diabetes. Investigators testing this therapeutic
potential reported the oral hypoglycemic agent, glipizide,
effects on insulin secretion in CF diabetics [8]. Glipizide
demonstrated a good response in early stages of disease,
but overtly diabetic CF subjects had a poor response to gli-
pizide alone. With the exception of this study, the medical
literature has primarily focused on diabetic control with
insulin therapy alone.
Inflammation may further impact insulin resistance in the
CF patient. Oral insulin sensitizing agents with anti-
inflammatory activity may provide a duel benefit in CFRD
and perhaps serve as an alternative agent for managing
diabetes. Metformin shares biguanide functional groups
in common with protease inhibitors, and metformin has
demonstrated protease inhibitor activity with exceptional
potency at therapeutic concentrations [9]. The thiazolid-
inediones have additionally demonstrated a counter-reg-
ulatory protective leukotriene inflammatory effect [10].
These agents have not been previously evaluated for
CFRD, secondary to concern of metabolic acidosis com-
plicated by metformin and the potential of hepatic toxic-
ity with thiazolidinediones [11].
This study reports the first clinical outcome for insulin
sensitizing agents with potential anti-inflammatory activ-
ity in the management of CFRD. The oral agents reviewed
above are compared to the insulin treatment group for
each clinical outcome. Clinical outcome measures fol-
lowed changes in glycosylated hemoglobin (HbA1c),
weight, forced expiratory volulme at 1 second (FEV1), and
alanine aminotransferase (ALT) for the duration of treat-
ment for each group.
Methods
Cystic Fibrosis Related Diabetes was diagnosed in 24
patients during a 10 year span from January 1992 through
December 2002 at the Dayton Adult Cystic Fibrosis Pro-
gram. Three CFRD patients receiving lung transplant were
excluded from this study secondary to immunosuppres-
sive therapy that included prednisone. A patient on com-
bination diabetic therapy during the study period was also
excluded. A total of 20 CFRD patients over this 10 year
period remained for this prospective study.
Patients elected treatment after informed consent was pro-
vided for all management options based on the benefit of
oral agents approved for use in type 2 diabetes mellitus
but with explicit concerns regarding risks of these agents
in context of the chronic illness and morbidity associated
with CF. The patients were further instructed that the
Cystic Fibrosis Foundation recommended the use of insu-
lin as the preferred method in treating CFRD. Both hospi-
tal and university institutional review boards approved of
this study protocol. Eight patients initially chose insulin,
5 patients sulfonylureas, 4 patients metformin (a bigua-
nide), and 3 patients thiazolidinediones.
The diagnosis of diabetes was established based on the
most current American Diabetes Association guidelines
during the decade span of the investigation based on a
minimum of two threshold fasting blood glucose and/or
random blood glucose values with symptoms. Weights
were used over BMI in this adult population as height data
remained constant. All weights were obtained standing,
without shoes on a balance scale calibrated yearly.
Patients were initiated on all oral agents starting with the
lowest dose recommended based on standard pharma-
ceutical recommendations. Patients were evaluated at
three month intervals at which time HbA1c levels were
obtained. All patients with HbA1c >7 had a dose increased
to the next recommended incremental level and followed
up 3 months later. Once an optimal HbA1c was achieved,
follow-up was spaced to 6 month intervals with HbA1c
levels drawn and adjusted around the HBA1c >7 parame-
ter. Insulin doses used consisted of split dosing 70/30
NPH/R ranging from 0.3 – 0.8 Units/kg. The oral medica-
tion dosing range required to achieve optimal control
expressed as a percentage of the highest recommend dose
was: sulfonylureas, 0.125 – 0.87; thiazolidinediones,
0.125 to 1.00; and metformin, 0.39 – 1.00. Compliance
was followed by timing of prescription renewal with min-
imal differences identified between treatment groups.
Statistical analyses
All continuous data are presented as the mean ± standard
deviation (SD). Comparisons between groups on baseline
data (age, weight, FEV1, and HbA1c) and treatment dura-
tion were made with one-way analysis of variance
(ANOVA), or Welch ANOVA if the variances within
groups were not equal. The changes in clinical variables
from the start to the end of the treatment period were
determined, and then were converted to changes/year to
adjust for differences in the duration of treatment.
Changes/year was compared between groups with either
one-way ANOVA or Welch ANOVA. P values less than
0.05 were considered statistically significant. Chi-squared
testing for nominal mortality data from the GraphPad
web based statistical program.
Results
All patient clinical profiles at the start of the study year,
1992, or at the time of CFRD diagnosis are summarized in
Table 1 and their clinical data during the study until death
or end of 2002 is graphed in the Figure. Baseline clinical
data for patients are grouped by the specific agent used to
manage CFRD and is summarized in Table 2. DataBMC Endocrine Disorders 2006, 6:4 http://www.biomedcentral.com/1472-6823/6/4
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reported in Table 3 reflect the variation over the course of
study from the baseline parameters identified in Table 2.
Seven individuals (35%) had HbA1c levels < 7% at the
time of diagnosis. All patients tolerated initial therapy
well, and no patient changed medical management due to
complications reported for these agents. Four patients
chose to discontinue insulin therapy for an oral agent sec-
ondary to inadequate glycosylated hemoglobin control of
7.0% while using insulin. Patient M1I4 weaned off 60
units of insulin per day with the best HbA1c control at
9.7% to metformin therapy achieving an averaged HbA1c
Table 1: Clinical profile of patients followed at start of study
Pt Age (yrs) Wt (kg) FEV1 (%) % HbA1c at Dx Rx Course (yrs) Clinical Data
I1 28 65.8 56 5.5 4 PI, LupusN, Deceased
I2 31 65.3 44 14.3 2 PI, Deceased
I3 13 41.9 57 9.3 4 PS
I4 33 54.3 18 10.0 2 PI, Deceased, RI*
I5 14 49.0 99 10.9 8 PI
I6 44 81.5 30 9.2 5 PI, Cor P, HTN, BPH
I7 24 53.0 57 7.3 3 PI, AIHS, RI
I8 21 70.5 93 9.8 10 PI
S1 29 75.5 71 7.1 1 PI
S2 17 33.6 33 8.1 2 PI, Deceased
S3 25 73.9 48 7.8 4 PI, Deceased
S4 33 97.5 83 6.3 1 PI, Bipolar, HTN
S5 18 49.7 30 6.6 1 PI, Deceased
M1I4 35 51.5 17 9.7 1 PI
M2 24 71.1 117 5.4 2 PI
M3I5 22 68.5 68 9.6 2 PI
M4 19 70.0 100 6.1 3 PI
M5 22 67.7 88 13.3 3 PI, Hepatic Cirrhosis
M6 15 41.8 85 8.9 5 PI
T1 29 58.0 47 13.3 2 PI
T2 20 44.4 23 5.1 1 PI
T3I6 49 85.5 29 9.2 2 PI, Cor P, HTN, BPH
T4I7 32 55.7 65 7.3 2 PI, AIHS, RI
T5S4 34 96.5 92 6.3 1 PI, Bipolar, HTN
T6 40 54.0 56 9.6 2 PI, Lupus, RI ABPA
Pt, patient (subscripts identify patient number, e.g. M1I4 was the first patient started on metformin and the fourth patient started on insulin); Rx 
Course (Yrs), represents the number of years that a patient received consecutive therapy with a specific class of agent; Mon, months; I, insulin; S, 
sulfonylurea; M, metformin; T, thiazolidinediones, FEV1, forced expiratory volume at 1 second; HbA1c, percent glycosylated hemoglobin; PI, 
pancreatic insufficient; PS, pancreatic sufficient; LupusN, lupus with nephritis; RI, renal insufficiency; Cor P, cor pulmonale; HTN, hypertension; BPH, 
benign prostatic hypertrophy; AIHS, autoimmune hypersplenism; ABPS, allergic bronchopulmonary aspergillosis. *Patient was switched back to 
insulin when diagnosed with renal insufficiency.
Table 2: Baseline clinical data
Variable Mean ± SD 
(Range)
Insulin (n = 8) Sulfonylurea (n = 5) Metformin (n = 6) Thiazoli-dinediones (n = 6) P Value
Age (Yrs) 26.0 ± 10.3 (13 – 44) 24.4 ± 6.9 (17 – 33) 22.8 ± 6.7 (15 – 35) 34.0 ± 9.9 (20 – 49) 0.166
ALT (U/L) 65.1 ± 24.1 (25 – 99) 42.0 ± 26.5 (14 – 73) 68.3 ± 28.1 (28 – 107 67.4 ± 8.4 (55 – 76) (n = 5) 0.250
FEV1 (%) 56.8 ± 28.0 (18 – 99) 53.0 ± 23.3 (30 – 83) 79.2 ± 34.5 (17 – 117) 52.0 ± 25.2 (3 – 92) 0.329
Weight (kg) 60.2 ± 12.9 (41.9 – 81.5) 66.0 ± 24.8 (33.6 – 97.5) 61.8 ± 12.2 (41.8 – 71.1) 65.7 ± 20.4 (44.4 – 96.5) 0.911
HbA1c 9.5 ± 2.6 (5.5 – 14.3) 7.2 ± 0.8 (6.3 – 8.1) 8.8 ± 2.8 (5.4 – 13.3) 8.0 ± 3.1 (5.1 – 13.3) 0.408
Treatment Duration (Yrs) 4.8 ± 2.9 (2 – 10) 1.8 ± 1.3 (1 – 4) 2.7 ± 1.4 (1 – 5) 1.8 ± 0.4 (1 – 2) 0.093
SD, standard deviation; Yrs, years; ALT, alanine aminotransferase; FEV1, forced expiratory volume at 1 second; HbA1c, percent glycosylated 
hemoglobin. P values for Age, ALT, FEV1, Weight, and HbA1c are from one-way analysis of variance (ANOVA); the P value for Treatment Duration is 
from Welch ANOVA for unequal group variances.BMC Endocrine Disorders 2006, 6:4 http://www.biomedcentral.com/1472-6823/6/4
Page 4 of 7
(page number not for citation purposes)
of 6.5%. This individual was the only patient in the met-
formin group with an FEV1 < 60% (refer to Figure), and
was insistent on using this agent despite strong advise to
select another treatment option. Patient T5S4 was well
controlled on a sulfonylurea, but requested to switch to a
thiazolidinedione.
Mortality rates from our study were highest among
patients in the sulfonylurea group (60%); followed by the
insulin group (37%); with no deaths observed from the
biguanide and thiazolidinedione treatment groups. Death
rates between treatment groups were not statistically sig-
nificant; P = 0.062. Sixty patients had been followed in
this adult center during this ten year period with a mortal-
ity rate of 23% observed in non-diabetics and 38% in dia-
betics, of which only a third were female, for a 1.7
increased diabetic mortality risk which is within the range
reported by other centers [12,13]. To date, only one
patient, T6, has been identified with diabetic complica-
tions. That patient came from the thiazolidinedione treat-
ment group and followed for systemic lupus. A
nephropathy developed 18 months after the diagnosis of
CFRD was made, with renal biopsy indicating diabetic
nephropathy. There have been no further reports of
abnormal urine microalbumin measures or retinal exam-
inations indicating microvascular disease in our patients.
Discussion
Results demonstrate no statistical advantage of one treat-
ment option over another in achieving overall glycemic
control. The number of patients in the various treatment
groups was most likely too small to achieve statistical sig-
nificance. More aggressive overall glycemic control for
CFRD may be necessary based on recent reports that
HbA1c underestimates a true glycemic index in CF patients
[14]. A reduced life span of red blood cells has recently
been reported through personal communication in cystic
fibrosis patients by researches in Houston, Texas, which
may reflect this underestimate of glycemic control. Studies
from the CF literature further demonstrate insulin
achieves only sub-optimal glycemic control based on
HbA1c outcomes, which is a significant concern when
placed in context with the data demonstrating that HbA1c
underestimates glycemic control. A retrospective study
out of Cleveland, Ohio, evaluated 22 patients on a flexible
meal-planning system targeting insulin boluses titrated to
each meal to control postprandial blood glucose excur-
sions and report glycosylated hemoglobin reductions
from 11.3 to 8.1% [15]. A prospective study from Paris,
France, followed 14 patients early in the diabetic course
on insulin therapy finding glycosylated hemoglobin val-
ues ranging from 6.6 to 7.8% [16]. A study conducted in
Houston, Texas compared subcutaneous insulin injec-
tions versus pump infusion demonstrated improved glyc-
emic control on the insulin pump in lowering HbA1c
values from 8.6 to 7.3% [17].
Morbidity and mortality data reported by centers using
insulin as standard management protocol provide con-
cern regarding optimizing clinical outcomes for CFRD.
Microvascular disease is reported in 23% of diabetic CF
patients [18] compared to 18% [19] in the non-CF dia-
betic population. The median age of survival for CFRD
patients is reported at 35.6 years compared to 47 years for
non-diabetics with CFRD females having a 7-fold mortal-
ity rate [20]. Significant mortality relative risks of 1.7 [12]
and 2.8 [13] have been reported in CFRD patients over
non-diabetic CF patients at two other centers.
Our center diabetic outcomes observed no adverse side
effects from oral agents during our decade experience of
treating CFRD. Caution must still be provided regarding
the potential side effects of using the newer oral agents in
managing CF diabetics, with the biguanide class present-
ing the most concerning risk of metabolic acidosis in the
CF patient, and therefore should not be offered to the
30% of CF patients that have well documented liver dis-
ease by the time they reach adulthood. This study has fur-
thermore identified four patients (20%) treated with renal
insufficiency, in which only the one case mentioned
above was attributed to diabetic nephropathy. Renal
insufficiency is an absolute contraindication to the use of
metformin and therefore, renal function must be fol-
lowed closely in all CF patients as they approach their
fourth and fifth decade of life. Likewise, this class of agent
should be utilized only in patients with good to moderate
Table 3: Clinical data variance over time
Variable Mean ± SD 
(Range)
Insulin (n = 8) Sulfonylurea (n = 5) Metformin (n = 6) Thiazoli-dinediones (n = 6) P Value
ALT (U/L) Change/Yr 1.8 ± 3.0 (-2.0 – 7.8) 4.7 ± 8.6 (-2.5 – 19.0) -2.8 ± 22.0 (-41.5 – 26.5) -1.1 ± 7.7 (-11.0 – 9.5) (n = 5) 0.757
FEV1 (%) Change/Yr -0.3 ± 3.3 (-3.9 – 6.3) 1.4 ± 9.6 (-9.0 – 13.0) -1.2 ± 3.2 (-7.0 – 1.5) 5.2 ± 7.8 (-2.5 – 20.0) 0.422
Weight (kg) Change/Yr 1.5 ± 2.2 (-1.2 – 6.3) 0.5 ± 2.2 (-2.4 – 2.7) 1.8 ± 3.9 (-3.3 – 8.5) 4.3 ± 6.0 (0.3 – 16.0) 0.384
HbA1c Change/Yr -0.3 ± 0.2 (-0.5 – 0.1) -0.8 ± 0.7 (-1.8 – -0.1) -1.1 ± 1.4 (-3.2 – 0.6) -0.6 ± 1.3 (-3.2 – 0.5) 0.283
SD, standard deviation; Yr, year; ALT, alanine aminotransferase; FEV1, forced expiratory volume at 1 second; HbA1c, percent glycosylated 
hemoglobin. P values for ALT and Weight are from one-way analysis of variance (ANOVA); P values for FEV1 and HbA1c are from Welch ANOVA 
for unequal group variances.BMC Endocrine Disorders 2006, 6:4 http://www.biomedcentral.com/1472-6823/6/4
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Clinical response in individual patients Figure 1
Clinical response in individual patients.
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pulmonary function. A recent study reported the safety of
metformin in 91 randomized patients by intention-to-
treat analysis with chronic obstructive pulmonary disease
(COPD). Lactic acid values did not differ in the groups on
or off metformin and correlated only with serum creati-
nine and body mass index. Mortality data were identical
in the two groups and they conclude that there is no
apparent reason that COPD patients should discontinue
metformin [21]. Additionally in a systematic review of
194 randomized control studies of metformin with other
diabetic agents, no fatal or nonfatal lactic acidosis events
were reported, with Poisson statistics at 95% confidence
intervals estimating lactic acidosis incidence at 8.1 and 9.9
cases per 100,000 [22].
A remarkable outcome from this center experience is the
observed 1.8 kg weight gain for patients taking met-
formin. Weight loss, is typically reported for the type 2
diabetic, and this outcome would not be tolerated in most
cystic fibrosis patients. The largest weight gain observed
by a patient in this group was a very respectable 27%. One
patient did lose 3% and another lost 7% of weight from
this treatment group which explains the large range in the
standard deviation of weight for this class. Neither of the
patients losing weight demonstrated a loss of pulmonary
function, with the patient losing 7% weight actually dem-
onstrating an FEV1 gain of 4% per year. The lower pulmo-
nary co-morbidity in the metformin group over other
groups may have influenced the higher weight gain
observed in this group. While this reduces the matching
between groups, statistical significance was not observed
over the insulin treatment group. Reasons behind a posi-
tive weight gain on metformin may relate to the cystic
fibrosis patient having a higher rate of protein breakdown
than non-CF patients [23]. Suppression of proteolysis by
protease inhibitor activity of metformin [9] may both
optimize overall nitrogen balance as well as inhibit insu-
lin degradation. There have not been any deaths from our
diabetic population maintained on metformin during our
decade long experience in treating CFRD. Liver enzymes
were least affected in this group as well as in the thiazoli-
dinedione treatment group which also demonstrated a net
decrease in liver enzyme changes during the course of
therapy, and both were within the range of change
observed with the other agents used in managing diabe-
tes.
This study is limited by the small number of patients
treated in a non-randomized, un-blinded fashion under
each therapeutic grouping. Additional bias is potentially
introduced by including baseline data of patients entering
the study diagnosed with CFRD prior to prospective data
gathering that was initiated in 1992, at which point all
patient data was prospectively reviewed in this cohort
study. Pulmonary treatment further evolved throughout
the duration of this review in relation to standards of air-
way clearance utilized and aerosolized maintenance ther-
apies that had become available to these patients.
Conclusion
Our CF center has adopted a rational approach to manag-
ing CFRD based on this observational experience.
1) Insulin appears to provide adequate response to
patients with significant lung disease (FEV1 < 60%), and is
likely the agent of choice to initiate management under
any inpatient setting.
2) After initial response to insulin, consideration should
be given to add a sulfonylurea or thiazolidinedione for
patients with stable liver functions, in attempt to wean off
insulin.
3) In the patient with significant diabetic onset with
HbA1c > 7 and relatively preserved pulmonary function
(FEV1 > 60%) with no documented liver disease, met-
formin can be used for initial management on an outpa-
tient basis. Close monitoring of metabolic profile, renal,
and hepatic function at quarterly intervals would be opti-
mal.
4) The thiazolidinedione class is an alternative agent for
outpatient management, particularly for the patient with
FEV1 close to or approaching 60% predicted. In this situa-
tion liver function testing should be monitored quarterly
at onset of therapy.
Our findings suggest that insulin may not be the most
beneficial therapeutic agent for the management of CFRD.
Oral agents that include the insulin sensitizing agents
appear to be safe and as effective as insulin. Larger rand-
omized control trials between insulin and the biguanide
or thiazolidinedione class of agents with potential anti-
inflammatory activity should be considered as alternative
therapy to insulin, especially in light of consistently poor
clinical outcomes reported for insulin therapy in the CF
patient population.
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